Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00556322 · BASELINE

Baseline characteristics

A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC) · Source last updated 2015-02-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      221
    2. group Id
      BG001
      value
      203
    3. group Id
      BG002
      value
      424
    units
    Participants
groups
  1. description
    Participants received either pemetrexed 500 mg/m\^2 every 21 days until disease progression, unacceptable toxicity or death or docetaxel 75 mg/m\^2 every 3 weeks until disease progression, unacceptable toxicity or death. Choice of comparator was left to the discretion of the investigator in countries where both treatments are registered to use and are commercially available for second line use (otherwise, docetaxel was administered), assigning the participant to either comparator depending upon the medical needs of the participant. Participants were required to receive concomitant treatment therapy as indicated in the product label.
    id
    BG000
    title
    Comparator
  2. description
    Participants received erlotinib, 150 mg, administered orally as a tablet, once daily until disease progression, unacceptable toxicity, or death.
    id
    BG001
    title
    Erlotinib
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.90
          value
          58.3
        2. group Id
          BG001
          spread
          9.64
          value
          58.6
        3. group Id
          BG002
          spread
          9.76
          value
          58.4
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          61
        2. group Id
          BG001
          value
          42
        3. group Id
          BG002
          value
          103
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          160
        2. group Id
          BG001
          value
          161
        3. group Id
          BG002
          value
          321
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Full Analysis Set (FAS): All participants randomized were included according to the therapy that they were randomized to receive in the FAS population.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      221
    2. group Id
      BG001
      value
      203
    3. group Id
      BG002
      value
      424
    units
    Participants
groups
  1. description
    Participants received either pemetrexed 500 mg/m\^2 every 21 days until disease progression, unacceptable toxicity or death or docetaxel 75 mg/m\^2 every 3 weeks until disease progression, unacceptable toxicity or death. Choice of comparator was left to the discretion of the investigator in countries where both treatments are registered to use and are commercially available for second line use (otherwise, docetaxel was administered), assigning the participant to either comparator depending upon the medical needs of the participant. Participants were required to receive concomitant treatment therapy as indicated in the product label.
    id
    BG000
    title
    Comparator
  2. description
    Participants received erlotinib, 150 mg, administered orally as a tablet, once daily until disease progression, unacceptable toxicity, or death.
    id
    BG001
    title
    Erlotinib
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.90
          value
          58.3
        2. group Id
          BG001
          spread
          9.64
          value
          58.6
        3. group Id
          BG002
          spread
          9.76
          value
          58.4
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          61
        2. group Id
          BG001
          value
          42
        3. group Id
          BG002
          value
          103
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          160
        2. group Id
          BG001
          value
          161
        3. group Id
          BG002
          value
          321
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Full Analysis Set (FAS): All participants randomized were included according to the therapy that they were randomized to receive in the FAS population.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice